An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment

John Christopher G. Gallagher, Prema B. Rapuri, Lynette M. Smith

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Context: Decreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population. Objective: The objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT. Design: This was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc. Setting: The study was conducted at an academic outpatient center. Participants: Four hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study. Intervention: Subjects were randomized to placebo, calcitriol 0.25 μg twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT. Main Outcome Measures: Cumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater. Results: Calcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Calcitriol
Creatinine
Estrogens
Placebos
Conjugated (USP) Estrogens
Therapeutics
Medroxyprogesterone Acetate
Intention to Treat Analysis
Progestins
Bone
Outpatients
Aging of materials
Outcome Assessment (Health Care)
Urine
Kidney
Bone and Bones
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{a3275cb1305d465097604cbc1f5152d3,
title = "An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment",
abstract = "Context: Decreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population. Objective: The objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT. Design: This was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc. Setting: The study was conducted at an academic outpatient center. Participants: Four hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study. Intervention: Subjects were randomized to placebo, calcitriol 0.25 μg twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT. Main Outcome Measures: Cumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater. Results: Calcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (",
author = "Gallagher, {John Christopher G.} and Rapuri, {Prema B.} and Smith, {Lynette M.}",
year = "2007",
month = "1",
doi = "10.1210/jc.2006-1153",
language = "English",
volume = "92",
pages = "51--58",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment

AU - Gallagher, John Christopher G.

AU - Rapuri, Prema B.

AU - Smith, Lynette M.

PY - 2007/1

Y1 - 2007/1

N2 - Context: Decreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population. Objective: The objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT. Design: This was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc. Setting: The study was conducted at an academic outpatient center. Participants: Four hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study. Intervention: Subjects were randomized to placebo, calcitriol 0.25 μg twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT. Main Outcome Measures: Cumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater. Results: Calcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (

AB - Context: Decreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population. Objective: The objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT. Design: This was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc. Setting: The study was conducted at an academic outpatient center. Participants: Four hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study. Intervention: Subjects were randomized to placebo, calcitriol 0.25 μg twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT. Main Outcome Measures: Cumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater. Results: Calcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (

UR - http://www.scopus.com/inward/record.url?scp=33846077677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846077677&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-1153

DO - 10.1210/jc.2006-1153

M3 - Article

C2 - 17032712

AN - SCOPUS:33846077677

VL - 92

SP - 51

EP - 58

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -